GSK’s (GSK) “Buy” Rating Reaffirmed at Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reissued by research analysts at Jefferies Financial Group in a report issued on Tuesday, October 20th, Digital Look reports. They currently have a GBX 2,500 price objective on the stock. Jefferies Financial Group‘s price target suggests a potential upside of 30.17% from the company’s current price.

GSK has been the subject of several other research reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a research report on Tuesday, September 29th. Finally, Berenberg Bank lifted their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Stock Performance

GSK traded up GBX 5.50 on Tuesday, reaching GBX 1,920.50. The stock had a trading volume of 36,958,707 shares, compared to its average volume of 12,484,483. The business’s 50-day moving average price is GBX 1,847.60 and its two-hundred day moving average price is GBX 1,949.27. GSK has a 12-month low of GBX 1,624.50 and a 12-month high of GBX 2,282. The company has a market cap of £76.96 billion, a P/E ratio of 16.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Sell-side analysts forecast that GSK will post 175.98 earnings per share for the current year.

Insider Activity

In related news, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal purchased 637 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. In the last three months, insiders bought 2,151 shares of company stock valued at $6,021,921. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.